Bimatoprost in the Treatment of Eyelash Hypotrichosis

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

-Male and female adult patients with eyelash hypotrichosis (inadequate eyelash growth).

Exclusion Criteria:

• Damage to eyelid area (scarring) that may prevent growth of eyelashes

• Active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye)

• Eye or eyelid surgery (including laser, refractive, intraocular filtering surgery, blepharoplasty) during the 3 months prior to screening

• Current eyelash implants of any kind

• Eyelash tint or dye application within 2 months of baseline

• Eyelash extensions application within 3 months of baseline

• Use of eyelash growth products within 6 months of baseline

• Treatments that may affect hair growth (minoxidil, cancer chemotherapeutic agents, etc) within 6 months prior to baseline.